Dutch Medicines Evaluation Board (CBG)

Dutch Medicines Evaluation Board (College ter Beoordeling van Geneesmiddelen) is responsible for authorization and follow-up of medicinal products in the Netherlands and collaborates with the European Medicines Agency. In PRIME-CKD the CBG-MEB is responsible for WP 4 aimed at optimization of biomarker qualification procedures with regulatory agencies.

People involved in Prime-CKD

Prof. Dr. Peter GM Mol

Prof. Dr. Peter GM Mol

Prof. Dr. Peter GM Mol, professor of drug regulatory science, University Medical Center Groningen, and senior clinical assessor at the CBG-MEB.

Dr. Marjon (A.M.G.) Pasmooij

Dr. Marjon (A.M.G.) Pasmooij

Dr. Marjon (A.M.G.) Pasmooij, head of the science department, CBG-MEB.

Dr. Viktoriia Starokozhko

Dr. Viktoriia Starokozhko

Dr. Viktoriia Starokozhko, clinical assessor, CBG-MEB.

Lysbeth Bakker, PhD (-candidate)

Lysbeth Bakker, PhD (-candidate)

Renkse Grupstra, PhD-candidate

Renkse Grupstra, PhD-candidate

Links